Nyrada Inc.

NYR

AU0000070195

Pharmaceuticals

Delayed Australian S.E. Other stock markets 01:08:18 2024-04-26 am EDT			5-day change	1st Jan Change
0.094 ^AUD	-2.08%		-4.08%	+327.27%

Apr. 18	Transcript : Nyrada Inc., Q3 2024 Earnings Call, Apr 18, 2024
Apr. 11	Transcript : Nyrada Inc. - Special Call

Nyrada Inc. Reports Earnings Results for the Full Year Ended June 30, 2021

August 30, 2021 at 02:54 am EDT

Nyrada Inc. announced earnings results for the full year ended June 30, 2021. For the full year, the company announced total revenue was AUD 2.340 million compared to AUD 1.125 million a year ago. Net loss was AUD 3.539 million compared to AUD 5.773 million a year ago. Basic loss per share from continuing operations was AUD 0.03 compared to AUD 0.09 a year ago.

Latest news about Nyrada Inc.

Transcript : Nyrada Inc., Q3 2024 Earnings Call, Apr 18, 2024	Apr. 17
Transcript : Nyrada Inc. - Special Call	Apr. 10
Nyrada Begins Animal Testing on NYR-BI03 Brain Injury Program	Apr. 09	MT
Nyrada Begins Good Laboratory Practice Preclinical Study for Brain Injury Drug Candidate	Mar. 27	MT
Nyrada Raises AU$1.8 Million via Placement	Mar. 05	MT
Nyrada Inc. Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 20	CI
Nyrada Secures AU$3.5 Million R&D Tax Rebate for Fiscal Year 2023; Shares Surge 30%	Dec. 08	MT
Nyrada Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-27	CI
Australian Shares Flat as June Unemployment Rate Remains at 3.5%	23-07-20	MT
Nyrada Halves Director Fees; Shares Jump 37%	23-07-20	MT
Nyrada Opts to Advance NYR-BI03 Brain Injury Drug Candidate	23-06-12	MT
Nyrada Completes Preclinical Studies on Cholesterol Lowering Medication	23-05-25	MT
Nyrada Completes Preclinical Dose Formulation for Cholesterol Lowering Medication	23-04-11	MT
Nyrada Inc. Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-23	CI
Nyrada Extends R&D Deal for Brain Injury Drug Candidate	23-01-18	MT
Nyrada Inc. Announces Collaboration with Walter Reed and UNSW Extended to 2025	23-01-17	CI
Nyrada Advances Preclinical Studies for Brain Injury Drug Candidate	23-01-10	MT
Nyrada Inc. Provides Update on the Progress of Its Brain Injury Program	23-01-10	CI
Nyrada Receives $804,600 R&D Tax Refund; Shares fall 11%	22-11-17	MT
Nyrada Inc. Announces Efficacy Study Published in Journal of Lipid Research	22-10-09	CI
Nyrada Inc. Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-29	CI
Nyrada Inc. Announces Board Changes	22-08-01	CI
Nyrada Validates Effectivity of Inhibitor Drug to Block Early Atherosclerosis; Shares Fall 6%	22-07-19	MT
Nyrada Delays Phase 1 Cholesterol Trial Due to Lockdown in China; Shares Fall 7%	22-06-28	MT
Nyrada Inc. Provides Cholesterol-Lowering Program Update	22-06-28	CI

Chart Nyrada Inc.

Duration

Period

More charts

Company Profile

Nyrada Inc. is a preclinical stage, drug development company specializing in small molecule drugs to treat cardiovascular and neurological diseases. The Companyâs two lead programs are focused on cholesterol-lowering and brain injury. These programs are developing an oral, small molecule cholesterol-lowering drug, and a drug to reduce secondary brain damage following a stroke or traumatic brain injury (TBI). Its Cholesterol-Lowering Program is an oral PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs. Its Brain Injury Program is developing a drug to block secondary brain damage that occurs following a stroke or TBI, such as severe head trauma from contact sports, a fall, or a motor vehicle accident. The Brain Injury Program is a neuroprotectant drug to reduce the impact of long-term disability in patients who suffer a traumatic brain injury or ischemic stroke. It is also developing new therapies.

Sector

Pharmaceuticals

Calendar

2024-05-15 - Extraordinary Shareholders Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NYRADA INC.	+327.27%	11.2M
NOVO NORDISK A/S	+24.17%	556B
JOHNSON & JOHNSON	-6.33%	354B
MERCK & CO., INC.	+19.90%	331B
ABBVIE INC.	+7.95%	296B
ASTRAZENECA PLC	+13.45%	233B
NOVARTIS AG	+6.04%	201B
ROCHE HOLDING AG	-10.51%	193B
PFIZER, INC.	-12.26%	143B
AMGEN INC.	-6.47%	144B